717
Views
10
CrossRef citations to date
0
Altmetric
Author's View

HLA class I as a predictor of clinical prognosis and CTL infiltration as a predictor of chemosensitivity in ovarian cancer

, , , , &
Article: e1005507 | Received 28 Dec 2014, Accepted 30 Dec 2014, Published online: 21 May 2015

Figures & data

Figure 1. (A) Monoclonal antibodies specific for HLA Class I. HLA class I genes are located on chromosome 6p and comprise HLA-A, -B, and -C. The monoclonal antibody HC-10 is reactive for HLA-B and -C. The monoclonal antibody EMR8–5 is reactive for HLA-A, -B, and -C. (B) Immunological cell death (ICD) might play a role in chemotherapy sensitivity in human ovarian cancer. Cancer cells undergoing immunologic cell death release calreticulin (CRT), adenosine triphosphate (ATP), and High Mobility Group Box 1 (HMGB1) and activate dendritic cells (DCs) to induce a cancer-specific cytotoxic T lymphocyte (CTL) response.

Figure 1. (A) Monoclonal antibodies specific for HLA Class I. HLA class I genes are located on chromosome 6p and comprise HLA-A, -B, and -C. The monoclonal antibody HC-10 is reactive for HLA-B and -C. The monoclonal antibody EMR8–5 is reactive for HLA-A, -B, and -C. (B) Immunological cell death (ICD) might play a role in chemotherapy sensitivity in human ovarian cancer. Cancer cells undergoing immunologic cell death release calreticulin (CRT), adenosine triphosphate (ATP), and High Mobility Group Box 1 (HMGB1) and activate dendritic cells (DCs) to induce a cancer-specific cytotoxic T lymphocyte (CTL) response.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.